Related coverage linked through entity extraction aliases.
May 05, 2026
Cellectar Biosciences expanded its global IP estate and announced oversubscribed financing of up to $140 million. The funding supports iopofosine I 131 regulatory filings and a confirmatory study in Waldenström macroglobulinemia.
May 05, 2026
Cellectar reported 12-month follow-up from the Phase 2b CLOVER WaM trial of iopofosine I 131 in relapsed or refractory Waldenström macroglobulinemia. In 55 patients, ORR was 83.6%, MRR was 61.8% and median duration of response was 17.8 months.
Mar 11, 2026
Recent studies demonstrate zanubrutinib delivers higher response rates, longer treatment persistence, and lower healthcare costs compared to acalabrutinib and ibrutinib across multiple B-cell malignancies, with particularly strong benefits in high-risk populations.
Mar 06, 2026
AbbVie is testing venetoclax in a Phase 2 study for adults with relapsed or refractory Waldenström macroglobulinemia or lymphoplasmacytic lymphoma in Japan, aiming to expand the drug into rare blood cancers.
